SG178867A1 - Synthesis of a neurostimulative piperazine - Google Patents

Synthesis of a neurostimulative piperazine

Info

Publication number
SG178867A1
SG178867A1 SG2012012878A SG2012012878A SG178867A1 SG 178867 A1 SG178867 A1 SG 178867A1 SG 2012012878 A SG2012012878 A SG 2012012878A SG 2012012878 A SG2012012878 A SG 2012012878A SG 178867 A1 SG178867 A1 SG 178867A1
Authority
SG
Singapore
Prior art keywords
piperazine
synthesis
neurostimulative
derivatized
useful
Prior art date
Application number
SG2012012878A
Other languages
English (en)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
Mark Mclaws
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG178867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of SG178867A1 publication Critical patent/SG178867A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
SG2012012878A 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine SG178867A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24
PCT/US2010/046537 WO2011028548A1 (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Publications (1)

Publication Number Publication Date
SG178867A1 true SG178867A1 (en) 2012-04-27

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012012878A SG178867A1 (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Country Status (22)

Country Link
US (2) US9278933B2 (cg-RX-API-DMAC10.html)
EP (1) EP2470182B1 (cg-RX-API-DMAC10.html)
JP (1) JP5727482B2 (cg-RX-API-DMAC10.html)
KR (1) KR101701362B1 (cg-RX-API-DMAC10.html)
CN (2) CN105693601A (cg-RX-API-DMAC10.html)
AU (1) AU2010289802C1 (cg-RX-API-DMAC10.html)
BR (1) BR112012004161B1 (cg-RX-API-DMAC10.html)
CA (1) CA2772080C (cg-RX-API-DMAC10.html)
CL (1) CL2012000493A1 (cg-RX-API-DMAC10.html)
DK (1) DK2470182T3 (cg-RX-API-DMAC10.html)
ES (1) ES2475721T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20140621T1 (cg-RX-API-DMAC10.html)
IL (1) IL218298A (cg-RX-API-DMAC10.html)
IN (1) IN2012DN02370A (cg-RX-API-DMAC10.html)
MX (1) MX2012002335A (cg-RX-API-DMAC10.html)
NZ (1) NZ598891A (cg-RX-API-DMAC10.html)
PL (1) PL2470182T3 (cg-RX-API-DMAC10.html)
PT (1) PT2470182E (cg-RX-API-DMAC10.html)
RU (1) RU2567390C2 (cg-RX-API-DMAC10.html)
SG (1) SG178867A1 (cg-RX-API-DMAC10.html)
SI (1) SI2470182T1 (cg-RX-API-DMAC10.html)
WO (1) WO2011028548A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101701362B1 (ko) * 2009-08-24 2017-02-01 뉴럴스템, 인크. 신경자극성 피페라진의 합성방법
WO2018048927A1 (en) * 2016-09-12 2018-03-15 Neuralstem, Inc. Amelioration of neural deficits associated with diabetes
WO2018075667A1 (en) * 2016-10-18 2018-04-26 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
EP4267561A1 (en) * 2020-12-23 2023-11-01 Baylor College of Medicine Small-molecule modulators of the orphan nuclear receptor tlx
MX2023014442A (es) 2021-06-03 2024-03-05 Alto Neuroscience Inc Metodo de tratamiento de pacientes deprimidos con cognicion deficiente y seleccion de otros pacientes que se beneficiarian de un agente de bencilpiperazin-aminopiridina.
JP2025540165A (ja) 2022-12-05 2025-12-11 アルト ニューロサイエンス,インコーポレーテッド 学習障害及び/または記憶障害または特定のeeg特性を有する患者におけるベンジルピペラジン-アミノピリジン系薬剤によるうつ病の有効な治療
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
MXPA04009414A (es) * 2002-03-29 2005-01-25 Schering Corp Alquilacion estereoselectiva de piperazinas quirales 2-metil-4-protegidas.
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
AU2003293409A1 (en) * 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
CA2537292C (en) * 2003-09-09 2013-04-02 F. Hoffmann-La Roche Ag 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
PE20060600A1 (es) 2004-10-29 2006-07-14 Banyu Pharma Co Ltd Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
EP1966144A1 (en) * 2005-12-20 2008-09-10 Novartis AG Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
KR101701362B1 (ko) * 2009-08-24 2017-02-01 뉴럴스템, 인크. 신경자극성 피페라진의 합성방법

Also Published As

Publication number Publication date
WO2011028548A1 (en) 2011-03-10
IL218298A0 (en) 2012-04-30
US20130005974A1 (en) 2013-01-03
AU2010289802C1 (en) 2015-04-16
US9481649B2 (en) 2016-11-01
CA2772080C (en) 2017-05-30
DK2470182T3 (da) 2014-07-21
KR101701362B1 (ko) 2017-02-01
RU2012111227A (ru) 2013-10-10
AU2010289802A1 (en) 2012-04-12
US20160090358A1 (en) 2016-03-31
EP2470182B1 (en) 2014-06-04
MX2012002335A (es) 2012-07-04
CA2772080A1 (en) 2011-03-10
CN105693601A (zh) 2016-06-22
NZ598891A (en) 2014-05-30
SI2470182T1 (sl) 2014-10-30
HRP20140621T1 (hr) 2014-11-21
BR112012004161B1 (pt) 2020-04-07
IN2012DN02370A (cg-RX-API-DMAC10.html) 2015-08-21
RU2567390C2 (ru) 2015-11-10
EP2470182A4 (en) 2013-04-24
PT2470182E (pt) 2014-07-24
US9278933B2 (en) 2016-03-08
BR112012004161A2 (pt) 2016-03-29
KR20120054642A (ko) 2012-05-30
PL2470182T3 (pl) 2015-05-29
HK1172844A1 (en) 2013-05-03
EP2470182A1 (en) 2012-07-04
ES2475721T3 (es) 2014-07-11
JP2013502462A (ja) 2013-01-24
CN102711764A (zh) 2012-10-03
AU2010289802B2 (en) 2014-10-02
JP5727482B2 (ja) 2015-06-03
CL2012000493A1 (es) 2012-09-28
IL218298A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
SG178867A1 (en) Synthesis of a neurostimulative piperazine
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MX2012003343A (es) Proceso para preparar compuestos azabiciclicos.
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
ZA201000022B (en) Novel amide derivative for inhibiting the growth of cancer cells
EP1887880A4 (en) PROCESS FOR PRODUCING ANIMAL FEED AND ETHANOL AND NEW FOOD
ZA201004217B (en) Use of bacteria for the production of bioenergy
ZA201102782B (en) Sporulation-deficient termophilic microorganisms for the production of ethanol
ZA200907811B (en) Process for the manufacture of p4o6
IL201245A0 (en) An improved process for the synthesis of solifenacin
MY160392A (en) Triptolide prodrugs
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
IL214437A0 (en) Process for the synthesis of cleistanthin
EP2484466A4 (en) Stock feeding apparatus
EP2501712A4 (en) PROCESS FOR SYNTHESIS OF AC-ARG-CYCLO- (CYS-D-ALA-HIS-D-PHE-ARG-TRP-CYS-) NH2
EP2158160A4 (en) PROCESS FOR PRODUCING POLYALUMINUM SALTS
IN2012DN02000A (cg-RX-API-DMAC10.html)
MX2011011442A (es) Uso de compuestos de 1-fenil-3-dimetilaminopropano para tratar dolor reumatoide.
MX2009012096A (es) Axomadol para tratamiento de dolor con artritis.
FR2950890B1 (fr) Procede de synthese de la 2-thiohistidine et analogues
EP2275423B8 (en) Process for the synthesis of paliperidone
WO2012051601A3 (en) Heteroarylthio compounds
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
LT2449066T (lt) Akmens anglies su žemu-vidutiniu anglies kiekiu desulfuracijos būdas